Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced Genedata Expressionist 6, which is a major new release of the award-winning enterprise system for omics data management. With new Refiner MS module capabilities for direct integration with leading mass spectrometry search engines, Genedata Expressionist 6 provides a platform for real-time biomarker discovery. New predefined workflow systems and visualization enhancements are among additional features, which combine to create a highly intuitive omics analysis environment. Genedata Expressionist 6 will be demonstrated at the 58th ASMS Conference on Mass Spectrometry (May 23 - 27; Booth #1).
“Genedata Expressionist integrates easily and seamlessly with Mascot to help scientists quickly identify and characterize proteins that are potential diagnostic markers or therapeutics,” said John Cottrell, director at Matrix Science, developers of the Mascot search engine. “Moreover, this integration provides direct access to Mascot from within the Genedata Expressionist workflows, which are unusually flexible and interactive. The ability to drill down rapidly into large and complex data sets combined with confident protein identifications provides a crucial advantage to users of Genedata Expressionist.”
From Raw Expression Data to Informative Biomarkers
Genedata Expressionist, built on a highly scalable architecture, is capable of handling extremely large data sets and studies. It provides a single-point-of-access for experimental, proprietary and public data including sample information, raw and pre-processed data, and analyses results with reports and documentation. The dedicated Refiner modules for microarray and next-generation sequencing data readily extend the system beyond classical expression data to address the entire biomarker discovery and development workflow. Integrated omics data management and mapping technology support data analysis, biological interpretation, and decision making across key technologies.
The release of Genedata Expressionist 6 strengthens the power of this enterprise system for biologists and biostatisticians alike. This major new release includes Genedata Analyst™. While also available as a standalone solution, Genedata Analyst is integral to the Genedata Expressionist system. It supports hundreds of users and billions of data points per user session. Capabilities for sophisticated data analysis and visualization combine with a comprehensive set of statistical approaches and interface to third-part algorithms.
Genedata Expressionist 6 also delivers advancements to the Refiner MS module, which include:
“This new version of Genedata Expressionist marks the ten-year anniversary of a proven industry solution that is continually developed in collaboration with commercial and academic partners,” said Dr. Othmar Pfannes, CEO of Genedata. “The refined and optimized levels of visualization and interactivity in Genedata Expressionist 6 create the foundation for a new generation of data expression and analysis, which has the potential to address a broad range of research initiatives.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.